MCPyV is under clinical development by Affini-T Therapeutics and currently in Phase II for Merkel Cell Carcinoma. According to GlobalData, Phase II drugs for Merkel Cell Carcinoma have a 15% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MCPyV’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FH-MCVA2TCR is under development for the treatment of merkel cell carcinoma. The therapeutic candidate comprises of autologous T cells which are lentiviral based genetically engineered to (Merkel cell polyomavirus) MCPyV-specific TCRs. It is administered through intravenous route.
Affini-T Therapeutics overview
Affini-T Therapeutics (Affini-T) is a biotechnology company that develops T-cell therapies for oncology and immunology indications. It is investigating T-cell receptors (TCR) which include KRAS G12V, KRAS G12D, Mutant P53, and MCPyV. The company offers T-cell receptors to treat solid tumors by targeting oncogenic and viral driver mutations. Its Merkel cell polyomavirus (MCPyV) is a specific T cell receptor (TCR) program for the treatment of PD-1 refractory Merkel cell carcinoma (MCC). Affini-T utilizes the TCR discovery platform to identify, characterize and select potent and safe naturally occurring TCRs expressed on T cells. It has operations in Boston and Seattle. Affini-T is headquartered in Watertown, Massachusetts, the US.
For a complete picture of MCPyV’s drug-specific PTSR and LoA scores, buy the report here.